The Cassels Brock & Blackwell antitrust team remains a strong player among Canada’s mid-market firms. Practice leader Chris Hersh says the team has grown on the margins in recent years, pulling in talented lawyers from other parts of the firm – including the litigation and IP practices – to help boost the capacity of the two-partner core group.
On the contentious side, the Cassels Brock group has handled franchise competition issues for client Quiznos, and it obtained intervener status in the bureau’s case against the Toronto Real Estate Board case for client Reality Sellers. In criminal matters, the firm has noted an uptick in enforcement and says it is involved in several major investigations, including the auto parts cartel probe. In mergers, the team has acted for Starlight Investments in its purchase of TransGlobe Apartment REIT, and Alexion Pharmaceuticals in its purchase of Enobia Pharma, among other matters.
The group currently looks as follows:
Partner and head of the department: Chris Hersh (416-869-5387 / [email protected])
Associates: Imran Ahmad
Significant 2012 deals for the group include:
Acting as counsel to Merlin Securities LLC in its purchase by Wells Fargo Securities
Acting as counsel to Westaim Corporation in its sale of JEVCO Insurance Company to Intact Financial Corporation
Acting as legal advisor to CF Industries Holdings, Inc. in its agreement to acquire Viterra Inc.’s Interest in Canadian Fertilizers Limited
Acting as counsel to Starlight Investments Ltd. in its $2.3 billion acquisition of TransGlobe Apartment Real Estate Investment Trust
Acting as counsel to Hilco (UK) Ltd. in its first Canadian transaction, the purchase of Kraus Group Acting as counsel to Alexion Pharmaceuticals, Inc. in its approximately $1.08 billion acquisition of Enobia Pharma Corp.
For all competition related inquiries, please contact Chris Hersh (416-869-5387 / [email protected]). For all inquires with regards to marketing for the Competition group, please contact Shenela Tavarayan (marketing coordinator – 416-860-6751 / [email protected])